IMUNON Files IND Application To Begin Human Testing Of IMNN-101; Expects Enrollment In Phase 1 Proof-Of-Concept Study Of DNA-Based Vaccine Technology To Begin In Q2
Portfolio Pulse from Happy Mohamed
IMUNON, Inc. (NASDAQ:IMNN) has filed an IND application with the FDA for IMNN-101, a DNA-based vaccine for COVID-19, with Phase 1 human trials expected to start in Q2 2024. The vaccine utilizes IMUNON's proprietary PlaCCine platform and aims to demonstrate superior durability and immune response compared to mRNA vaccines. Preclinical data shows promising results, and the company aims to attract partners for further development.
March 13, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IMUNON, Inc. has filed an IND application for its DNA-based COVID-19 vaccine, IMNN-101, with Phase 1 trials expected to start in Q2 2024. The vaccine shows potential for superior durability and immune response, with the company looking to attract development partners.
Filing an IND application and moving towards human trials is a significant step in vaccine development, indicating progress and potential. The positive preclinical data and the vaccine's potential advantages over mRNA vaccines could attract investor interest and partnerships, likely leading to a positive short-term impact on IMUNON's stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100